Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

ADMA BIOLOGICS, INC. (ADMA) Stock Forecast 2025 - AI Price Prediction & Analysis

ADMA BIOLOGICS, INC. (ADMA) AI Stock Price Forecast & Investment Analysis

ADMA BIOLOGICS, INC. Stock Price Chart and Technical Analysis

Loading ADMA BIOLOGICS, INC. interactive price chart and technical analysis...

ADMA BIOLOGICS, INC. (ADMA) - Comprehensive Stock Analysis & Investment Research

Deep dive into ADMA BIOLOGICS, INC.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about ADMA BIOLOGICS, INC., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For ADMA BIOLOGICS, INC.: ADMA BIOLOGICS, INC. operates in the Life Sciences sector, establishing it as a mid-cap growth opportunity.

ADMA BIOLOGICS, INC. (Stock Symbol: ADMA) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry.

The organization employs approximately 302 professionals worldwide .

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing ADMA BIOLOGICS, INC.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ADMA BIOLOGICS, INC.: With $488M in annual revenue and 129.8% net margin, the company demonstrates exceptional profitability.

Annual Revenue: $488 million generating a 129.8% net profit margin .

Market Capitalization: $4793 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -65.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for ADMA BIOLOGICS, INC. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For ADMA BIOLOGICS, INC.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for ADMA BIOLOGICS, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: ADMA BIOLOGICS, INC.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For ADMA BIOLOGICS, INC.: Market positioning analysis based on available financial and operational metrics.

ADMA BIOLOGICS, INC. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 1167.1% gross margin, indicating strong pricing power and operational efficiency.

ADMA BIOLOGICS, INC. (ADMA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for ADMA BIOLOGICS, INC. stock analysis.

Loading ADMA BIOLOGICS, INC. comprehensive fundamental analysis and insider trading data...

Deep dive into ADMA BIOLOGICS, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if ADMA BIOLOGICS, INC. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For ADMA BIOLOGICS, INC.: With a P/E ratio of 22.88, the market moderately values the company's earnings.

P/E Ratio 22.88x
P/B Ratio 11.12x
Market Cap $4793M
EPS $0.89
Book Value/Share $1.81
Revenue/Share $2.05
FCF/Share $-1.30
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently ADMA BIOLOGICS, INC. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ADMA BIOLOGICS, INC.: An ROE of -65.4% indicates room for improvement in shareholder value creation.

ROE -65.4%
ROA -28.8%
ROIC -26.8%
Gross Margin 1167.1%
Operating Margin 715.9%
Net Margin 129.8%
EBT Margin -83.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess ADMA BIOLOGICS, INC.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For ADMA BIOLOGICS, INC.: A current ratio of 7.60 indicates strong liquidity.

Current Ratio 7.60x
Quick Ratio 3.01x
D/E Ratio 1.15x
Financial Leverage 2.43x
Interest Coverage -4.9x
Working Capital $134M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal ADMA BIOLOGICS, INC.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For ADMA BIOLOGICS, INC.: Free cash flow of $-119M indicates cash challenges that need attention.

Operating Cash Flow $-105M
Free Cash Flow $-119M
Capital Spending $-14M
FCF/Sales -126.5%
CapEx/Sales 14.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively ADMA BIOLOGICS, INC. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For ADMA BIOLOGICS, INC.: An asset turnover of 0.35x suggests room for improvement in asset utilization.

Asset Turnover 0.35x
Receivables Turnover 4.6x
Inventory Turnover 0.8x
Fixed Assets Turnover 1.7x
Days Sales Outstanding 80 days
Days Inventory 487 days
Payables Period 55 days
Cash Conversion Cycle 512 days
Understanding Financial Statement Data

What these metrics mean: Key figures from ADMA BIOLOGICS, INC.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For ADMA BIOLOGICS, INC.: With annual revenue of $488M, ADMA BIOLOGICS, INC. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $488M
R&D Expense $2M
SG&A Expense $50M
Cost of Goods Sold $178M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 78%
Cash & Short-term Investments 23%
Total Liabilities 59%
Short-term Debt 26%
Accounts Receivable 8%
Inventory 45%
Dividend & Shareholder Information
Shares Outstanding 238M
Growth Metrics (YoY)
EPS Growth 1.8%

Latest ADMA BIOLOGICS, INC. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting ADMA BIOLOGICS, INC. (ADMA) stock price and investment outlook.

📰 We are currently updating our news feed for ADMA BIOLOGICS, INC.. Check back soon for the latest market analysis and company updates.

ADMA BIOLOGICS, INC. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of ADMA BIOLOGICS, INC. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS Unlock Forecast - 30 Days FREE Trial $114M -1.9x 1.2x
ABP Unlock Forecast - 30 Days FREE Trial $17M x 0.0x
ACLX Unlock Forecast - 30 Days FREE Trial $3955M -74.1x 9.0x
ACOG Unlock Forecast - 30 Days FREE Trial $98M x 2.9x
ADAP Unlock Forecast - 30 Days FREE Trial $77M -13.2x -11.8x
ADMA Unlock Forecast - 30 Days FREE Trial $4793M 22.9x 11.1x
ADPT Unlock Forecast - 30 Days FREE Trial $2664M -4.6x 13.0x
ADVM Unlock Forecast - 30 Days FREE Trial $90M -1.8x 2.2x
AGEN Unlock Forecast - 30 Days FREE Trial $150M -0.5x -0.5x
AGTX Unlock Forecast - 30 Days FREE Trial $2M x x
AIM Unlock Forecast - 30 Days FREE Trial $4M -0.5x -183.3x
AIMI Unlock Forecast - 30 Days FREE Trial $4M x x
ALEC Unlock Forecast - 30 Days FREE Trial $143M -1.2x 2.5x
ALGS Unlock Forecast - 30 Days FREE Trial $59M -19.2x 0.8x
ALLO Unlock Forecast - 30 Days FREE Trial $319M -1.4x 1.0x
AMGN Unlock Forecast - 30 Days FREE Trial $177646M 25.4x 18.5x
APGE Unlock Forecast - 30 Days FREE Trial $4552M -20.5x 4.3x
APTOF Unlock Forecast - 30 Days FREE Trial $4M x x
ARMP Unlock Forecast - 30 Days FREE Trial $21M -1.0x -1.6x
ARTV Unlock Forecast - 30 Days FREE Trial $92M x 0.7x
ATHA Unlock Forecast - 30 Days FREE Trial $17M -0.2x 0.6x
ATRA Unlock Forecast - 30 Days FREE Trial $109M 17.8x -1.1x
ATYR Unlock Forecast - 30 Days FREE Trial $77M -3.6x 1.0x
AURA Unlock Forecast - 30 Days FREE Trial $407M -4.9x 2.6x
AUTL Unlock Forecast - 30 Days FREE Trial $417M x 1.6x
AVXL Unlock Forecast - 30 Days FREE Trial $379M -17.3x 4.0x
BCAB Unlock Forecast - 30 Days FREE Trial $47M -1.1x 1.0x
BCDA Unlock Forecast - 30 Days FREE Trial $15M -0.6x 5.9x
BCLI Unlock Forecast - 30 Days FREE Trial $7M -4.9x -0.9x
BCRX Unlock Forecast - 30 Days FREE Trial $1648M -12.1x -4.0x
BDTX Unlock Forecast - 30 Days FREE Trial $152M 7.1x 1.2x
BEAM Unlock Forecast - 30 Days FREE Trial $2930M -12.6x 3.0x
BIIB Unlock Forecast - 30 Days FREE Trial $26615M 16.6x 1.8x
CABA Unlock Forecast - 30 Days FREE Trial $245M -1.6x 1.8x
CADL Unlock Forecast - 30 Days FREE Trial $293M -4.6x 3.7x
CCCC Unlock Forecast - 30 Days FREE Trial $198M -2.6x 1.3x
CDTX Unlock Forecast - 30 Days FREE Trial $6464M -1.0x 15.3x
CELZ Unlock Forecast - 30 Days FREE Trial $7M -3.4x 1.2x
CERO Unlock Forecast - 30 Days FREE Trial $0M x -196.2x
CGEM Unlock Forecast - 30 Days FREE Trial $624M -4.1x 1.4x
CGEN Unlock Forecast - 30 Days FREE Trial $141M x 2.8x
CGON Unlock Forecast - 30 Days FREE Trial $3501M x 5.1x
CGTX Unlock Forecast - 30 Days FREE Trial $145M -0.5x 4.0x
CHRS Unlock Forecast - 30 Days FREE Trial $139M 0.9x 1.6x
CLDI Unlock Forecast - 30 Days FREE Trial $10M -0.9x 1.5x
CMPX Unlock Forecast - 30 Days FREE Trial $986M -4.8x 4.7x
CPMV Unlock Forecast - 30 Days FREE Trial $4M x x
CRBU Unlock Forecast - 30 Days FREE Trial $178M -1.5x 1.3x
CRDF Unlock Forecast - 30 Days FREE Trial $153M -4.0x 3.1x
CRIS Unlock Forecast - 30 Days FREE Trial $17M -0.3x -2.9x
CRSP Unlock Forecast - 30 Days FREE Trial $5339M -12.1x 2.8x
CSBR Unlock Forecast - 30 Days FREE Trial $90M -17.8x 25.7x
CVM Unlock Forecast - 30 Days FREE Trial $41M -0.9x 5.8x
DBVT Unlock Forecast - 30 Days FREE Trial $1808M -3.3x 34.2x
DBVTF Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
DNA Unlock Forecast - 30 Days FREE Trial $528M -13.9x 0.9x
DNLI Unlock Forecast - 30 Days FREE Trial $2949M -8.7x 3.2x
DTIL Unlock Forecast - 30 Days FREE Trial $66M -2.2x 4.0x
DYAI Unlock Forecast - 30 Days FREE Trial $34M -7.3x 13.2x
EDIT Unlock Forecast - 30 Days FREE Trial $226M -0.8x 16.8x
ELUT Unlock Forecast - 30 Days FREE Trial $28M -1.4x -0.1x
ENGN Unlock Forecast - 30 Days FREE Trial $419M 3.7x 2.1x
ENTX Unlock Forecast - 30 Days FREE Trial $105M 8.5x 6.9x
ENZN Unlock Forecast - 30 Days FREE Trial $3M x 6.9x
ESLA Unlock Forecast - 30 Days FREE Trial $76M -3.1x -16.9x
EXEL Unlock Forecast - 30 Days FREE Trial $11893M 17.5x 5.5x
EXOZ Unlock Forecast - 30 Days FREE Trial $133M x 24.8x
FATE Unlock Forecast - 30 Days FREE Trial $131M -1.3x 0.6x
FDMT Unlock Forecast - 30 Days FREE Trial $513M -3.0x 1.4x
FENC Unlock Forecast - 30 Days FREE Trial $212M 1758.3x -39.7x
FNCH Unlock Forecast - 30 Days FREE Trial $22M -0.1x 1.5x
FTII Unlock Forecast - 30 Days FREE Trial $3M x -0.7x
FTIIU Unlock Forecast - 30 Days FREE Trial $3M x -0.8x
GILD Unlock Forecast - 30 Days FREE Trial $150555M 18.6x 7.0x
GLUE Unlock Forecast - 30 Days FREE Trial $1057M 50.5x 4.3x
GNTA Unlock Forecast - 30 Days FREE Trial $37M x 2.9x
GPLB Unlock Forecast - 30 Days FREE Trial $0M x x
HALO Unlock Forecast - 30 Days FREE Trial $7443M 12.5x 14.8x
HLVX Unlock Forecast - 30 Days FREE Trial $105M -0.6x 0.7x
HUMA Unlock Forecast - 30 Days FREE Trial $199M -3.3x 49.4x
IBRX Unlock Forecast - 30 Days FREE Trial $2265M -3.6x -4.1x
IKT Unlock Forecast - 30 Days FREE Trial $112M -1.0x 1.5x
IMCR Unlock Forecast - 30 Days FREE Trial $2030M x 5.1x
IMVT Unlock Forecast - 30 Days FREE Trial $3999M -14.5x 7.7x
INBX Unlock Forecast - 30 Days FREE Trial $1273M -6.8x 34.6x
INKT Unlock Forecast - 30 Days FREE Trial $43M -1.5x -1.4x
INMB Unlock Forecast - 30 Days FREE Trial $41M -2.5x 1.6x
INTS Unlock Forecast - 30 Days FREE Trial $20M -2.2x 2.7x
IOVA Unlock Forecast - 30 Days FREE Trial $844M -4.5x 1.2x
IPSC Unlock Forecast - 30 Days FREE Trial $47M -0.7x 0.3x
IVVD Unlock Forecast - 30 Days FREE Trial $480M -0.4x 5.2x
JSPR Unlock Forecast - 30 Days FREE Trial $49M -3.2x 4.2x
KLRS Unlock Forecast - 30 Days FREE Trial $102M x 2.4x
KLTO Unlock Forecast - 30 Days FREE Trial $33M x 3.4x
KOD Unlock Forecast - 30 Days FREE Trial $1312M -2.5x 55.4x
KRYS Unlock Forecast - 30 Days FREE Trial $6786M 34.1x 6.0x
KYMR Unlock Forecast - 30 Days FREE Trial $4751M -17.8x 5.0x
KYTX Unlock Forecast - 30 Days FREE Trial $342M x 2.3x
LADX Unlock Forecast - 30 Days FREE Trial $0M x x
LCTX Unlock Forecast - 30 Days FREE Trial $397M -4.7x 18.0x
LENZ Unlock Forecast - 30 Days FREE Trial $787M -6.7x 4.1x
LIMN Unlock Forecast - 30 Days FREE Trial $28M x x
LXEO Unlock Forecast - 30 Days FREE Trial $508M -0.4x 4.2x
MAZE Unlock Forecast - 30 Days FREE Trial $2048M x 5.4x
MGTX Unlock Forecast - 30 Days FREE Trial $686M -3.4x 231.3x
MGX Unlock Forecast - 30 Days FREE Trial $61M x 0.3x
MRNA Unlock Forecast - 30 Days FREE Trial $10831M -3.2x 1.2x
NBIX Unlock Forecast - 30 Days FREE Trial $15504M 36.2x 5.2x
NMRA Unlock Forecast - 30 Days FREE Trial $373M -3.9x 2.8x
NVAX Unlock Forecast - 30 Days FREE Trial $1115M 3.3x 32.4x
OCGN Unlock Forecast - 30 Days FREE Trial $383M -4.3x 108.3x
OTLK Unlock Forecast - 30 Days FREE Trial $78M -0.2x -2.3x
PALI Unlock Forecast - 30 Days FREE Trial $10M -0.2x 3.2x
PASG Unlock Forecast - 30 Days FREE Trial $28M -0.6x 0.9x
PCVX Unlock Forecast - 30 Days FREE Trial $6044M -20.4x 2.1x
PHGE Unlock Forecast - 30 Days FREE Trial $114M 1.5x 10.8x
PLUR Unlock Forecast - 30 Days FREE Trial $28M -1.4x -9.1x
PLX Unlock Forecast - 30 Days FREE Trial $139M 23.0x 2.6x
PMCB Unlock Forecast - 30 Days FREE Trial $5M -2.6x 0.1x
PRME Unlock Forecast - 30 Days FREE Trial $685M -1.5x 4.2x
PROK Unlock Forecast - 30 Days FREE Trial $146M x 0.0x
QGEN Unlock Forecast - 30 Days FREE Trial $10564M x 3.0x
QNCX Unlock Forecast - 30 Days FREE Trial $219M -1.7x 206.4x
REPL Unlock Forecast - 30 Days FREE Trial $816M -3.8x 3.1x
RGEN Unlock Forecast - 30 Days FREE Trial $9286M 5342.7x 4.5x
RGNX Unlock Forecast - 30 Days FREE Trial $663M -1.8x 4.1x
RLAY Unlock Forecast - 30 Days FREE Trial $1381M -2.0x 2.3x
RVMD Unlock Forecast - 30 Days FREE Trial $15109M -11.1x 9.5x
RXRX Unlock Forecast - 30 Days FREE Trial $2420M -4.7x 2.3x
SABS Unlock Forecast - 30 Days FREE Trial $188M -2.3x 1.1x
SANA Unlock Forecast - 30 Days FREE Trial $1328M -2.1x 6.8x
SCLX Unlock Forecast - 30 Days FREE Trial $121M -0.4x -0.3x
SCNI Unlock Forecast - 30 Days FREE Trial $6238M -287.8x 793.9x
SGMO Unlock Forecast - 30 Days FREE Trial $120M -1.6x 19.2x
SLDB Unlock Forecast - 30 Days FREE Trial $445M -0.9x 2.0x
SLXN Unlock Forecast - 30 Days FREE Trial $9M x 1.3x
SNTI Unlock Forecast - 30 Days FREE Trial $55M -1.1x 6.7x
SRRK Unlock Forecast - 30 Days FREE Trial $4483M -18.5x 18.3x
SRZN Unlock Forecast - 30 Days FREE Trial $142M -0.5x 2.4x
STRO Unlock Forecast - 30 Days FREE Trial $68M -1.0x -2.5x
TARA Unlock Forecast - 30 Days FREE Trial $215M -2.1x 1.6x
TARS Unlock Forecast - 30 Days FREE Trial $3474M -12.4x 10.4x
TCBPY Unlock Forecast - 30 Days FREE Trial $7M x 6.5x
TCRX Unlock Forecast - 30 Days FREE Trial $144M -4.6x 1.0x
TECX Unlock Forecast - 30 Days FREE Trial $397M -8.9x 1.5x
TIL Unlock Forecast - 30 Days FREE Trial $87M -1.1x 0.7x
TNYA Unlock Forecast - 30 Days FREE Trial $205M -2.5x 2.5x
TRML Unlock Forecast - 30 Days FREE Trial $1233M -3.5x 4.8x
TSHA Unlock Forecast - 30 Days FREE Trial $1386M -3.0x 6.3x
TTNP Unlock Forecast - 30 Days FREE Trial $6M -0.5x 2.2x
TVGN Unlock Forecast - 30 Days FREE Trial $82M x -29.3x
TWST Unlock Forecast - 30 Days FREE Trial $1989M -12.6x 4.2x
VACH Unlock Forecast - 30 Days FREE Trial $67M 6.6x 0.0x
VACHU Unlock Forecast - 30 Days FREE Trial $67M x 0.0x
VCEL Unlock Forecast - 30 Days FREE Trial $1860M 142.2x 5.8x
VIR Unlock Forecast - 30 Days FREE Trial $879M -2.0x 1.1x
VIVS Unlock Forecast - 30 Days FREE Trial $6M x 0.8x
VOR Unlock Forecast - 30 Days FREE Trial $70M -0.6x 3.9x
VXRT Unlock Forecast - 30 Days FREE Trial $85M -0.9x 3.2x
VYGR Unlock Forecast - 30 Days FREE Trial $237M 570.6x 1.1x
WINT Unlock Forecast - 30 Days FREE Trial $1M -0.4x 0.2x
XFOR Unlock Forecast - 30 Days FREE Trial $32M 6.4x 0.5x
ZEOX Unlock Forecast - 30 Days FREE Trial $14M x x
ZIVO Unlock Forecast - 30 Days FREE Trial $44M -31.3x -2.0x

Frequently Asked Questions - ADMA BIOLOGICS, INC. Stock Forecast

How accurate are ADMA BIOLOGICS, INC. stock predictions?

Our AI model shows a 18% Spearman correlation coefficient for ADMA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence ADMA BIOLOGICS, INC. stock price forecasts?

Our analysis considers ADMA BIOLOGICS, INC.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is ADMA BIOLOGICS, INC. a good investment in 2025?

Based on our AI analysis, ADMA BIOLOGICS, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are ADMA BIOLOGICS, INC. forecasts updated?

ADMA BIOLOGICS, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced ADMA BIOLOGICS, INC. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for ADMA BIOLOGICS, INC. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...